• HIV infection in non-pregnant women:
    • PO 400mg/100mg BD
    • May give 800mg/200mg OD in patients with <3 lopinavir resistance-associated substitutions.
    • PO 500mg/125mg BD (2 x 200mg/50 mg + 100mg/25mg) when used with efavirenz, fosamprenavir, nelfinavir or nevirapine
  • HIV infection in pregnant women:
    • PO 400mg/100mg BD.
    • PO 500mg/125mg BD (2 x 200mg/50 mg + 100mg/25mg) when used with efavirenz, fosamprenavir, nelfinavir or nevirapine
  • HIV infection in children:
    • 2 weeks-6 months: PO solution: 300mg/75mg per m² OR 16mg/4mg per kg BD
      • NOT to be administered with efavirenz, nevirapine, fosamprenavir or nelfinavir in infants aged <6 months
    • Oral solution: 6 months-18 years (not receiving concomitant efavirenz, nevirapine, fosamprenavir or nelfinavir):
      • 230mg/57.5 mg/m² per dose BD. Max: 400mg/dose of lopinavir OR
      • 7kg to <15kg: 12mg/kg/dose BD based on lopinavir component
      • 15-40kg: 10mg/kg/dose BD based on lopinavir component. Max 400mg/100mg BD
      • >40kg: As adults; 400mg/100mg BD
    • Oral tablets: 6 months-18 years (not receiving concomitant efavirenz, nevirapine, fosamprenavir, or nelfinavir)
      • ≥15-25 kg OR ≥0.6-<0.9m²: 200mg/50 mg (two 100/25 mg-tab) BD
      • >25-35kg OR ≥0.9-<1.4m²: 300mg/75mg (three 100/25 mg-tab) BD
      • >35 kg or ≥1.4 m²: 400mg/100mg BD
    • 6 months-18 years (coadministered with efavirenz, nevirapine, fosamprenavir, or nelfinavir)
      • 300mg/75mg/m²/dose BD. Max 400mg/dose of lopinavir
  • Tablet:
    • 200mg/50mg
    • 100mg/25mg
  • Oral pellets:
    • 40mg/10mg
  • Suspension:
    • 80mg/20mg per mL
  • Administer BD in pediatric patients <18 years. Do NOT administer OD
  • Tablets: Administer with or without food
  • Oral solution: Administer with food
  • Avoid oral solution in pregnant patients

Protease inhibitors antiretroviral

It binds to active site of HIV protease, preventing mature virus particle formation

  • Diarrhea
  • Nausea
  • Vomiting
  • Hypercholesterolemia
  • Hypertriglyceridemia
  • Taste changes (peds patients)
  • Elevated ALT/AST
  • Hyperamylasemia
  • Asthenia
  • Musculoskeletal pain
  • Headache
  • Abdominal pain
  • Hyperglycemia
  • Anxiety
  • Rash
  • Insomnia
  • Hyperbilirubinemia
  • Hypersensitivity reaction
  • Weight loss
  • Lipodystrophy
  • Decreased appetite
  • Dyspepsia
  • Neuropathy
  • Respiratory infection
  • Skin infection
  • Gastroenteritis
  • Anemia
  • Hypersensitivity to components
  • Neonates <14 days old with postmenstrual age <42 weeks
  • Pregnancy (PO solution form)
  • Congenital long QT syndrome
  • Hypokalemia
  • Hemodialysis (OD regimen use)
  • Breastfeeding
  • Alfuzosin
  • Amiodarone
  • Astemizole
  • Cobicistat
  • Bromocriptine
  • Budesonide
  • Cobimetinib
  • Conivaptan
  • Dihydroergotamine
  • Disulfiram
  • Elbasvir/grazoprevir
  • Elagolix
  • Eletriptan
  • Eliglustat
  • Elvitegravir/cobicistat/emtricitabine/tenofovir df
  • Enzalutamide
  • Eplerenone
  • Ergoloid mesylates
  • Ergonovine
  • Finerenone
  • Flibanserin
  • Goserelin
  • Irinotecan
  • Isavuconazonium sulfate
  • Ivabradine
  • Lefamulin
  • Leuprolide
  • Lomitapide
  • Lonafarnib
  • Lovastatin
  • Lurasidone
  • Mavacamten
  • Methylergonovine
  • Naloxegol
  • Pacritinib
  • Pimozide
  • Pitavastatin
  • Regorafenib
  • Salmeterol
  • Simvastatin
  • Tinidazole
  • Tipranavir
  • Triazolam
  • Ubrogepant
  • Venetoclax
  • Voclosporin
  • Voriconazole

                          Drug Status

Availability Prescription only
Pregnancy Category C (Oral solution)
Breastfeeding Contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Aluvia 100mg/25mg Tablet 60’s Abbvie Phillips Therapeutics
Aluvia 200mg/50mg Tablet 120’s Abbvie Phillips Therapeutics
Kaletra 80mg/20mg per mL Suspension 300mL Abbvie Phillips Therapeutics